| Literature DB >> 32324944 |
Sascha Knauer1,2, Niklas Koch1, Christina Uth1, Reinhard Meusinger2, Olga Avrutina2, Harald Kolmar2.
Abstract
The growing interest in synthetic peptides has prompted the development of viable methods for their sustainable production. Currently, large amounts of toxic solvents are required for peptide assembly from protected building blocks, and switching to water as a reaction medium remains a major hurdle in peptide chemistry. We report an aqueous solid-phase peptide synthesis strategy that is based on a water-compatible 2,7-disulfo-9-fluorenylmethoxycarbonyl (Smoc) protecting group. This approach enables peptide assembly under aqueous conditions, real-time monitoring of building block coupling, and efficient postsynthetic purification. The procedure for the synthesis of all natural and several non-natural Smoc-protected amino acids is described, as well as the assembly of 22 peptide sequences and the fundamental issues of SPPS, including the protecting group strategy, coupling and cleavage efficiency, stability under aqueous conditions, and crucial side reactions.Entities:
Keywords: green chemistry; peptide synthesis; protecting groups; sustainability; water-based peptide synthesis
Mesh:
Substances:
Year: 2020 PMID: 32324944 PMCID: PMC7496111 DOI: 10.1002/anie.202003676
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336
Scheme 1General Scheme of ASPPS.
Figure 1Top: Synthesis of Smoc‐chloride 2 from Fmoc‐chloride 1. Middle: synthetic access to N‐Smoc‐amino acids. Bottom: Solution of 2 under irradiation with UV light.
Synthesized N‐Smoc‐amino acids.
|
No. |
Abbreviation |
Yield [%] |
|---|---|---|
|
|
Smoc‐ |
87.2 |
|
|
Smoc‐ |
86.9 |
|
|
Smoc‐ |
85.7 |
|
|
Smoc‐ |
85.1 |
|
|
Smoc‐ |
90.4 |
|
|
Smoc‐ |
86.7 |
|
|
Smoc‐ |
85.1 |
|
|
Smoc‐ |
90.8 |
|
|
Smoc‐ |
88.2 |
|
|
Smoc‐Gly‐OH |
93.7 |
|
|
Smoc‐ |
92.4 |
|
|
Smoc‐ |
86.6 |
|
|
Smoc‐ |
88.9 |
|
|
Smoc‐ |
90.6 |
|
|
Smoc‐ |
88.7 |
|
|
Smoc‐ |
87.4 |
|
|
Smoc‐ |
95.1 |
|
|
Smoc‐ |
93.7 |
|
|
Smoc‐ |
85.8 |
|
|
Smoc‐ |
90.0 |
|
|
Smoc‐ |
87.9 |
|
|
Smoc‐ |
92.2 |
|
|
Smoc‐ |
89.2 |
|
|
Smoc‐ |
90.7 |
|
|
Smoc‐ |
86.9 |
|
|
Smoc‐ |
89.7 |
|
|
Smoc‐ |
91.4 |
|
|
Smoc‐ |
87.2 |
|
|
Smoc‐β‐Ala‐OH |
92.5 |
|
|
Smoc‐Aib‐OH |
57.8 |
Comparison of protecting schemes for Boc‐SPPS, Fmoc‐SPPS, and ASPPS.
|
Boc‐SPPS[a] |
Fmoc‐SPPS |
ASPPS |
|---|---|---|
|
Boc‐Arg(Tos)‐OH |
Fmoc‐Arg(Pbf)‐OH |
Smoc‐Arg‐OH |
|
Boc‐Asn(Trt)‐OH |
Fmoc‐Asn(Trt)‐OH |
Smoc‐Asn‐OH |
|
Boc‐Asp(OBzl)‐OH |
Fmoc‐Asp(OtBu)‐OH |
Smoc‐Asp(OtBu)‐OH |
|
Boc‐Cys(Acm)‐OH |
Fmoc‐Cys(Trt)‐OH |
Smoc‐Cys(Trt)‐OH |
|
Boc‐Gln(Trt)‐OH |
Fmoc‐Gln(Trt)‐OH |
Smoc‐Gln‐OH |
|
Boc‐Glu(OBzl)‐OH |
Fmoc‐Glu(OtBu)‐OH |
Smoc‐Glu(OtBu)‐OH |
|
Boc‐His(Dnp)‐OH |
Fmoc‐His(Trt)‐OH |
Smoc‐His(Trt)‐OH[a] |
|
Boc‐Lys(Cbz)‐OH |
Fmoc‐Lys(Boc)‐OH |
Smoc‐Lys(Boc)‐OH |
|
Boc‐Ser(Bzl)‐OH |
Fmoc‐Ser(tBu)‐OH |
Smoc‐Ser(OtBu)‐OH |
|
Boc‐Thr(Bzl)‐OH |
Fmoc‐Thr(tBu)‐OH |
Smoc‐Thr(OtBu)‐OH |
|
Boc‐Trp(For)‐OH |
Fmoc‐Trp(Boc)‐OH |
Smoc‐Trp(Boc)‐OH[b] |
|
Boc‐Tyr(Bzl)‐OH |
Fmoc‐Tyr(tBu)‐OH |
Smoc‐Tyr(OtBu)‐OH |
[a] Smoc‐His was also synthesized without side‐chain protection. [b] Smoc‐Trp was also synthesized without side‐chain protection. Acm=acetamidomethyl, Bzl=benzyl, Cbz=benzyloxycarbonyl, Dnp=2,4‐dinitrophenyl, For=formyl, OBzl=benzyl ester, Tos=tosyl, Trt=trityl.
Overview of the synthesized peptides.
|
No. |
Peptide sequence |
Solvent |
Yield [mg] (%)[a] |
|---|---|---|---|
|
|
H‐AGELS‐NH2 (pentapeptide‐31) |
water |
13.7 (57.7) |
|
|
H‐GPQGPQ‐OH (hexapeptide‐9) |
water |
9.2 (38.7) |
|
|
H‐EEMQRR‐HN2 (hexapeptide‐3) |
water |
21.7 (51.3) |
|
|
Ac‐EEMQRR‐HN2 (acetylhexapeptide‐3) |
water |
18.7 (42.1) |
|
|
Leu‐Enkephalin amide H‐YGGFL‐NH2 |
water |
19.6 (70.8) |
|
|
Met‐Enkephalin H‐YGGFM‐OH |
30 % MeCNaq |
9 (63) |
|
|
Leu‐Enkephalin H‐YGGFL‐OH |
30 % MeCNaq |
10.3 (71.8) |
|
|
(ACP) 65‐74 H‐VQAAIDYING‐OH |
50 % MeCNaq |
18 (36) |
|
|
(ACP) 65‐74 H‐VQAAIDYING‐NH2 |
50 % MeCNaq |
23 (46) |
|
|
H‐GPRP‐OH |
water |
8 (38) |
|
|
Smoc‐VVIA‐NH2 |
water |
26 (67) |
|
|
Smoc‐DIIW‐OH |
water |
22 (50) |
|
|
Smoc‐E(OtBu)K(Boc)R(Pbf)S(tBu)C(Trt)‐OH |
50 % MeCNaq |
18 (44) |
|
|
H‐CYEIS‐NH2 |
30 % MeCNaq |
15 (48.9) |
|
|
H‐ANKPG‐NH2 |
30 % MeCNaq |
13 (35.6) |
|
|
Pal‐GHK‐OH[b] |
20 % EtOHaq |
14.1 (54.2) |
|
|
Pal‐GQPR‐OH[b] |
20 % EtOHaq |
18.7 (59.7) |
|
|
H‐GPRPA‐NH2 Vialox |
30 % MeCNaq |
12 (48.4) |
|
|
oxytocin |
30 % MeCNaq |
18 (35.7) |
|
|
vasopressin |
30 % MeCNaq |
20 (39.7) |
|
|
heptaarginine |
30 % MeCNaq |
23 (41.4) |
|
|
leuphasyl |
20 % MeCNaq |
17.3 (57.8) |
[a] Calculated from the average loading. [b] Pal: Palmitic acid.
Figure 2Selected RP‐HPLC traces of crude 55 (a standard validation sequence), 61 (a model peptide for racemization studies), 67 (natural peptide vasopressin), and 68 (an arginine‐rich peptide). The HPLC traces show peptides prior to any purification step.
Figure 3Sulfo‐tag purification concept. Two model peptides, 49 and 77, were assembled considering the deficiencies of all the amino acids to facilitate the formation of by‐products. Peptide 77 was synthesized in a classic DMF‐based synthesis to show applicability in Fmoc‐SPPS.
Figure 4Fluorescence monitoring of the coupling and deprotection steps during ASPPS of the peptide H‐Leu‐Val‐Ala‐Ile‐Gly‐NH2.